Healthcare [ 5/11 ] | Biotechnology [ 72/148 ]
CA | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 3, 23 | 0.08 Increased by +132.00% | 0.20 Decreased by -60.00% |
| May 4, 23 | -0.18 Increased by +33.33% | -0.24 Increased by +25.00% |
| Feb 28, 23 | -0.18 Increased by +28.00% | -0.27 Increased by +33.33% |
| Nov 3, 22 | -0.06 Increased by +84.62% | -0.17 Increased by +64.71% |
| Aug 4, 22 | -0.25 Increased by +32.43% | -0.22 Decreased by -13.64% |
| May 10, 22 | -0.27 Increased by +32.50% | -0.27 |
| Feb 28, 22 | -0.25 Decreased by -400.00% | -0.27 Increased by +7.41% |
| Nov 3, 21 | -0.39 Decreased by -39.29% | -0.33 Decreased by -18.18% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 41.49 M Increased by +47.19% | -11.49 M Increased by +67.64% | Decreased by -27.70% Increased by +78.02% |
| Mar 31, 23 | 34.41 M Increased by +59.12% | -26.21 M Increased by +30.36% | Decreased by -76.16% Increased by +56.23% |
| Dec 31, 22 | 28.43 M Increased by +21.50% | -26.05 M Increased by +21.84% | Decreased by -91.60% Increased by +35.67% |
| Sep 30, 22 | 55.78 M Increased by +280.30% | -8.99 M Increased by +82.11% | Decreased by -16.12% Increased by +95.30% |
| Jun 30, 22 | 28.19 M Increased by +325.85% | -35.52 M Increased by +24.45% | Decreased by -125.98% Increased by +82.26% |
| Mar 31, 22 | 21.63 M Increased by +2.27 K% | -37.63 M Increased by +25.31% | Decreased by -174.01% Increased by +96.84% |
| Dec 31, 21 | 23.40 M Decreased by -53.22% | -33.32 M Decreased by -47.73% | Decreased by -142.38% Decreased by -215.80% |
| Sep 30, 21 | 14.67 M Increased by +50.48 K% | -50.26 M Decreased by -47.53% | Decreased by -342.64% Increased by +99.71% |
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.